Daré Bioscience (NASDAQ:DARE) Receives Buy Rating from HC Wainwright

HC Wainwright reissued their buy rating on shares of Daré Bioscience (NASDAQ:DARE) in a report published on Thursday, Benzinga reports. HC Wainwright currently has a $12.00 price target on the biotechnology company’s stock.

Separately, Maxim Group restated a “hold” rating on shares of Daré Bioscience in a research report on Wednesday, August 14th.

Daré Bioscience Trading Up 4.3 %

Shares of DARE stock opened at $3.65 on Thursday. The stock has a 50 day moving average of $3.41 and a 200 day moving average of $3.95. The stock has a market cap of $30.74 million, a P/E ratio of -0.95 and a beta of 1.39. Daré Bioscience has a twelve month low of $3.05 and a twelve month high of $7.56.

Daré Bioscience (NASDAQ:DARE) last announced its quarterly earnings results on Monday, August 12th. The biotechnology company reported $1.52 earnings per share for the quarter, beating the consensus estimate of ($0.57) by $2.09. The company had revenue of $0.02 million for the quarter, compared to analysts’ expectations of $0.60 million. On average, research analysts predict that Daré Bioscience will post -0.27 earnings per share for the current fiscal year.

Institutional Trading of Daré Bioscience

A hedge fund recently raised its stake in Daré Bioscience stock. Renaissance Technologies LLC lifted its position in Daré Bioscience, Inc. (NASDAQ:DARE) by 2.1% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 778,700 shares of the biotechnology company’s stock after acquiring an additional 15,800 shares during the period. Renaissance Technologies LLC owned 9.25% of Daré Bioscience worth $262,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 6.70% of the stock is currently owned by hedge funds and other institutional investors.

About Daré Bioscience

Daré Bioscience, Inc, a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older.